Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes of Food and Drug Control, Beijing, People's Republic of China.
Hum Vaccin Immunother. 2021 Jul 3;17(7):2197-2204. doi: 10.1080/21645515.2020.1857201. Epub 2021 Feb 10.
Meningococcal meningitis caused by is a reportable infectious disease in China, due to the high incidence of meningitis in the era before the availability of vaccines. The disease incidence was markedly reduced after meningococcal vaccination was introduced in the 1980s. Currently, there are polysaccharide, conjugate, and combined vaccine formulations against meningococcal meningitis in the Chinese market, almost all of which are produced by domestic manufacturers. It is necessary to further enhance national meningococcal surveillance to improve the level of prevention and control of meningococcus. However, the immune efficacy and persistence of immunity of vaccines should be monitored. More importantly, additional investments should be made to develop serogroup B meningococcal vaccines.
脑膜炎奈瑟菌引起的流脑是中国的乙类传染病，由于在疫苗问世之前，流脑发病率较高。自 20 世纪 80 年代脑膜炎球菌疫苗问世以来，发病率明显下降。目前，中国市场上有脑膜炎球菌多糖疫苗、结合疫苗和联合疫苗，几乎全部由国内厂家生产。有必要进一步加强国家脑膜炎球菌监测，提高流脑防控水平。但是，疫苗的免疫效果和免疫持久性需要监测。更重要的是，需要增加投入来研发 B 群脑膜炎球菌疫苗。
